ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7–30. PubMed PMID: 28055103.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108. PubMed PMID: 25651787.
   PubMed Web of Science ®Google Scholar
• Cancer stat facts: female breast cancer NCI surveillance, epidemiology, and end results (SEER) program. [Cited 2017 Oct]. Available from: https://seer.cancer.gov/statfacts/html/breast.html
   Google Scholar
• Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013 Aug;274(2):113–126. PubMed PMID: 23844915; PubMed Central PMCID: PMCPMC3711134.
   PubMed Web of Science ®Google Scholar
• Michiels S, Pugliano L, Marguet S, et al. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol. 2016 Jun;27(6):1029–1034. PubMed PMID: 26961151.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. PubMed PMID: 2470152.
   PubMed Web of Science ®Google Scholar
• Hudziak RM, Lewis GD, Winget M, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989 Mar;9(3):1165–1172. PubMed PMID: 2566907; PubMed Central PMCID: PMCPMC362707.
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Apr 01;20(7):1800–1808. PubMed PMID: 11919237.
   PubMed Web of Science ®Google Scholar
• Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001 May 15;19(10):2587–2595. PubMed PMID: 11352950.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783–792. PubMed PMID: 11248153.
   PubMed Web of Science ®Google Scholar
• Herceptin FDA label. [Cited 2017 Oct]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf
   Google Scholar
• Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724–734. PubMed PMID: 25693012.
   PubMed Web of Science ®Google Scholar
• Nelson KM, Gallagher PC. Biosimilars lining up to compete with Herceptin–opportunity knocks. Expert Opin Ther Pat. 2014 Nov;24(11):1149–1153. PubMed PMID: 25307085.
   PubMed Web of Science ®Google Scholar
• Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013 Sep;6(8):469–478. PubMed PMID: 24991376; PubMed Central PMCID: PMCPMC4031732.
   PubMedGoogle Scholar
• Macdonald JC, Hartman H, Jacobs IA. Regulatory considerations in oncologic biosimilar drug development. MAbs. 2015;7(4):653–661. PubMed PMID: 25961747; PubMed Central PMCID: PMCPMC4622730
   PubMed Web of Science ®Google Scholar
• Jackisch C, Lammers P, Jacobs I. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars. Breast. 2017 Apr;32:199–216. PubMed PMID: 28236776.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA. 2017 Jan 03;317(1):37–47. PubMed PMID: 27918780.
   PubMed Web of Science ®Google Scholar
• NIH US National Library of Medicine [10/01/2017]. [Cited 2017 Oct]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Stebbing J, Baranau Y, Baryash V, et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 2017 Jul;18(7):917–928. PubMed PMID: 28592386.
   PubMed Web of Science ®Google Scholar
• Pivot X, Bondarenko I, Dvorkin M, et al. A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer. J Clin Oncol. 2017;35(15_suppl):509.
   Google Scholar
• Pivot X, Curtit E, Lee YJ, et al. A randomized phase I pharmacokinetic study comparing biosimilar candidate SB3 and trastuzumab in healthy male subjects. Clin Ther. 2016 Jul;38(7):1665e3–1673 e3. PubMed PMID: 27368117. DOI:10.1016/j.clinthera.2016.06.002
   Web of Science ®Google Scholar
• Lammers P, Dank M, Masetti R, et al. A randomized, double-blind study of PF-05280014 (a potential biosimilar) vs trastuzumab, both given with docetaxel (D) and carboplatin (C), as neoadjuvant treatment for operable human epidermal growth factor receptor 2-positive (HER21) breast cancer. ESMO; 2017.
   Google Scholar
• Pegram M, Tan-Chiu E, Freyman A, et al. A randomized, double-blind study of PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in combination with paclitaxel, as first-line treatment for HER2-positive metastatic breast cancer. ESMO; 2017.
   Google Scholar
• Hanes V, Chow V, Zhang N, et al. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects. Cancer Chemother Pharmacol. 2017 May;79(5):881–888. PubMed PMID: 28341959; PubMed Central PMCID: PMCPMC5403841.
   PubMed Web of Science ®Google Scholar
• Hanes V, Born T, Chow V, et al. Comparative similarity of ABP 980 and trastuzumab: results of functional similarity and human pharmacokinetic assessment. Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 2015 Dec 8-12; San Antonio, TX: Cancer Res.
   Google Scholar
• Hanes V, Born T, Chow V, et al. Functional and human pharmacokinetic similarity of ABP 980 and trastuzumab. European Breast Cancer Conference; 2016: EUROPEAN JOURNAL OF CANCER
   Google Scholar
• Von Minckwitz G, Ponomarova O, Morales S, et al. Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer. Esmo. Abstract 151PD. Annals of Oncology. 2017;28(suppl_5):v43-v67.
   Google Scholar
• Bosworth T. Phase 3 study confirms clinical equivalence for ABP 980 and reference trastuzumab: the center for biosimilars; 2017. [Cited 2017 Oct]. Available from: http://www.centerforbiosimilars.com/conferences/esmo-2017/phase-3-study-confirms-clinical-equivalence-for-abp-980-and-reference-trastuzumab
   Google Scholar
• Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry U.S. department of health and human services food and drug administration center for drug evaluation and research (CDER) center for biologics evaluation and research (CBER); 2015. [Cited 2017 Oct]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
   Google Scholar
• Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15;22(6):1063–1070. PubMed PMID: 15020607.
   PubMed Web of Science ®Google Scholar
• Garattini L, Van de Vooren K, Curto A. Cost-effectiveness of trastuzumab in metastatic breast cancer: mainly a matter of price in the EU?. Health Policy. 2015 Feb;119(2):212–216. PubMed PMID: 25523144.
   PubMed Web of Science ®Google Scholar
• Parkinson B, Pearson SA, Viney R. Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. Eur J Health Econ. 2014 Jan;15(1):93–112. PubMed PMID: 23436142.
   PubMed Web of Science ®Google Scholar
• Pichon-Riviere A, Garay OU, Augustovski F, et al. Implications of global pricing policies on access to innovative drugs: the case of trastuzumab in seven latin american countries. Int J Technol Assess Health Care. 2015 Jan;31(1–2):2–11. PubMed PMID: 25989703.
   PubMed Web of Science ®Google Scholar
• Harvey RD. Science of biosimilars. J Oncol Pract. 2017 Sep;13(9_suppl):17s–23s. PubMed PMID: 28898589.
   PubMed Web of Science ®Google Scholar